Opexa Therapeutics’ Therapy For Multiple Sclerosis Featured In FOX Television News Story
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company
®, a novel T-cell immunotherapy for the
treatment of multiple sclerosis (MS), is pleased to announce that Tcelna
has been featured...
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna ®, a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), is pleased to announce that Tcelna has been featured in a FOX Atlanta Channel 5 Newscast titled “New Therapy Could Battle Autoimmune Diseases.” The story by FOX Medical Team reporter Beth Galvin highlights Opexa’s ongoing Phase IIb clinical trial in secondary progressive MS and provides an interview with Dr. Ben Thrower, the Medical Director at the Multiple Sclerosis Institute at Shepherd Center in Atlanta, Georgia, and one of the principal investigators in Opexa's Abili-T clinical trial. The story can be accessed at http://www.myfoxatlanta.com/story/23138444/new-therapy-could and from Opexa’s website. “Tcelna offers hope to many individuals suffering from MS,” commented Dr. Thrower. “We are currently enrolling patients in the Phase IIb clinical trial at our facility and maintain hope that Tcelna could become a safe and effective alternative for the treatment of MS. The therapy acts to restore the function of the body’s immune system to enable the body to fight the disease directly. Since the therapy uses the patient’s own T-cells, the risk of complication is low. Importantly, Tcelna is being developed for secondary progressive MS, as currently, there are limited treatment options for patients with this form of MS.” "The MS Institute at Shepherd Center in Atlanta is an important site in our Phase IIb clinical trial,” commented Neil K. Warma, President and Chief Executive Officer of Opexa. “We appreciate the significant effort of Dr. Thrower and his team and their commitment to the MS community. The Abili-T trial is progressing well and we have over 30 sites in the United States and Canada committed to the ongoing enrollment of patients with secondary progressive MS. In addition, we are encouraged with the coverage by FOX News of the potential our T-cell therapy has to effectively treat MS and address a community with a great unmet need, as well as to make a real difference in the lives of the patients."